v3.24.1.u1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash Flows from Operating Activities    
Net loss $ (46,833,186) $ (43,862,197)
Adjustments to reconcile net loss to net cash used in operating activities:    
Goodwill impairment loss 3,873,079  
Intangible asset impairment loss 2,277,921  
Intangible asset impairment loss   3,500,000
Depreciation and amortization 6,474,256 2,115,015
Amortization of intangible asset 1,091,250 1,030,625
Noncash lease expense 514,665 116,583
Stock-based compensation 2,628,276 4,085,737
Change in fair value of common stock warrants   (11,020)
Change in fair value of contingent consideration (107,355) (3,452,015)
Unrealized (gain) loss on investments (123,019) 1,701,443
Deferred tax liability (571,120) (3,288,937)
Payment of contingent consideration (1,073,145)  
Gain on sale of discontinued operations (1,467,451)  
Increase (decrease) in cash arising from changes in assets and liabilities, net of acquisitions:    
Accounts receivable (293,698) (15,967)
Other assets (368,124) 12,233,529
Prepaid expenses and other current assets 2,731,454 58,656
Grant receivable 1,524,522 (206,163)
Contract receivables   24,526,231
Inventory (909,158) 5,844,000
Income tax receivable 600,877 443,968
Right-of-use assets (277,807) (12,158,238)
Deposits 42,439 (64,560)
Accounts payable (116,908) 3,299,326
Deferred revenue 771,133 1,583,308
Accrued expenses and other liabilities (1,921,496) (3,126,158)
Other long-term liabilities   (53,530)
Net Cash Used In Operating Activities (31,532,595) (5,700,364)
Cash Flows from Investing Activities    
Purchase of short-term investments (483,497) (2,457,348)
Sale of short-term investments 34,237,270 53,243,519
Purchases of property and equipment (1,985,557) (20,117,998)
Disposal of property and equipment 220,802 388,103
Proceeds from sale of Elusys Therapeutics 247,577  
Acquisition of Elusys Therapeutics, net of cash paid   2,719,899
Payment of contingent consideration   (22,784,571)
Net Cash Provided by Investing Activities 32,236,595 10,991,604
Cash Flows from Financing Activities    
Proceeds from the issuance of common stock 65,624 59,692
Payment of contingent consideration (6,434,115) (4,735,000)
Repayments of principal under finance lease (2,583,583) (231,633)
Net Cash Used In Financing Activities (8,952,074) (4,906,941)
Effect of exchange rate changes on cash and cash equivalents (1,555) (3,624)
Net (Decrease) Increase in Cash and Cash Equivalents (8,249,629) 380,675
Cash and Cash Equivalents - Beginning of the Period 8,434,554 8,053,879
Cash and Cash Equivalents - End of the Period 184,925 8,434,554
Supplemental Disclosure for Cash Flow Information:    
Right-of-use assets obtained upon operating lease commencements 895,578 6,348,346
Right-of-use assets obtained upon financing lease commencements 9,983,504 15,477,515
Right-of-use assets surrendered upon financing lease modifications (3,092,408) (81,752)
Right-of-use assets obtained upon financing lease modifications 70,033 37,654
Right-of-use assets obtained upon operating lease modifications 87,839  
Supplemental disclosure of non-cash investing and financing activities:    
Purchases of property and equipment included in accounts payable   288,807
Contingent and deferred cash consideration related to Elusys acquisition   42,853,685
Reconciliation of cash and cash equivalents at December 31, 2023 and 2022    
Cash and cash equivalents included in current assets of discontinued operations   5,242,840
Cash and cash equivalents of continuing operations 184,925 3,191,714
Total cash and cash equivalents $ 184,925 $ 8,434,554

Source

HTML PDF
ZIP